Gelteq Limited Ordinary Shares (GELS)vsHaleon plc (HLN)
GELS
Gelteq Limited Ordinary Shares
$0.57
-1.67%
HEALTHCARE · Cap: $5.97M
HLN
Haleon plc
$10.04
-1.28%
HEALTHCARE · Cap: $43.98B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 2363613% more annual revenue ($11.15B vs $471,800). HLN leads profitability with a 14.5% profit margin vs 0.0%. HLN earns a higher WallStSmart Score of 51/100 (C-).
GELS
Avoid33
out of 100
Grade: F
HLN
Buy51
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 48.9% year-over-year
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -24.9% — below average capital efficiency
Expensive relative to growth rate
2.2% revenue growth
Grey zone — moderate risk
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : GELS
The strongest argument for GELS centers on Price/Book, Revenue Growth. Revenue growth of 48.9% demonstrates continued momentum.
Bull Case : HLN
The strongest argument for HLN centers on Price/Book, Operating Margin.
Bear Case : GELS
The primary concerns for GELS are EPS Growth, Market Cap, Profit Margin.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Key Dynamics to Monitor
GELS profiles as a hypergrowth stock while HLN is a value play — different risk/reward profiles.
GELS is growing revenue faster at 48.9% — sustainability is the question.
HLN generates stronger free cash flow (792M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
HLN scores higher overall (51/100 vs 33/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gelteq Limited Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. The company is headquartered in Caulfield, Australia.
Visit Website →Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?